1. Home
  2. WSBF vs PRTA Comparison

WSBF vs PRTA Comparison

Compare WSBF & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Waterstone Financial Inc. (MD)

WSBF

Waterstone Financial Inc. (MD)

N/A

Current Price

$21.28

Market Cap

378.8M

Sector

Finance

ML Signal

N/A

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$9.66

Market Cap

449.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WSBF
PRTA
Founded
1921
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
378.8M
449.7M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
WSBF
PRTA
Price
$21.28
$9.66
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$19.00
AVG Volume (30 Days)
50.9K
357.2K
Earning Date
04-23-2026
05-07-2026
Dividend Yield
3.79%
N/A
EPS Growth
46.53
N/A
EPS
0.84
0.26
Revenue
N/A
$814,000.00
Revenue This Year
N/A
$1,111.38
Revenue Next Year
N/A
N/A
P/E Ratio
$25.27
$37.25
Revenue Growth
N/A
N/A
52 Week Low
$14.52
$7.73
52 Week High
$21.50
$11.80

Technical Indicators

Market Signals
Indicator
WSBF
PRTA
Relative Strength Index (RSI) 64.90 62.19
Support Level $20.45 $8.10
Resistance Level N/A $10.11
Average True Range (ATR) 0.39 0.37
MACD -0.02 0.06
Stochastic Oscillator 100.00 90.32

Price Performance

Historical Comparison
WSBF
PRTA

About WSBF Waterstone Financial Inc. (MD)

Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The majority of its revenue comes from the Community Banking segment.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: